Roche Palo Alto LLC

Syntex (u.s.a.) Inc.

Afferent Pharmaceuticals, Inc.

F. Hoffmann-la Roche Ag

European Molecular Biology Laboratory

Savira Pharmaceuticals Gmbh

Roche Diagnostics Operations, Inc.

Other

Amgen Inc.

Hoffmann-la Roche Inc.

Merck Sharp + Dohme Corp.

Roche Diagnostics Gmbh

Ronald Charles Hawley

Michael Patrick Dillon

Li Chen

Minmin Yang

Lichun Feng

Eric Brian Sjogren

John W Patterson

David John Morgans, Jr

David Bernard Smith

Peter H Nelson

Robert James Weikert

Chris Allen Broka

Todd Richard Elworthy

David Garrett Loughhead

Ann M Waltos

Alejandra Trejo

Alicia Cervantes

Dean R Artis

Teresa Lara

Fidencio Franco

Prabha N Ibrahim

Anthony P Ford

Alam Jahangir

David Scott Carter

Daniel Warren Parish

Joel R Gever

Mario Fernandez

David Michael Goldstein

Helmut Heinrich Buschmann

Sung-Sau So

Mark Smith

Salvatore Joseph Salamone

Francisco Xavier Talamas

Mitali Ghoshal

Erasmus Huber

Sharada Shenvi Labadie

Eva Hoess

Stephen Cusack

Allan R Dorn

Norbert Handler

Alfred Sui-Ting Lui

Oliver Szolar

Andrea Wolkerstorfer

Francisco X Talamas

Achyutharao Sidduri

Gerald F Sigler

Raymond Hui

Clara Jeou Jen Lin

Mario Fern Andez

Francisco X Talam As

Juan Carlos Jaen

Timothy David Cushing

John C Rohloff

Xiaolin Hao

Marc Labelle

Xiao He

David Louis Clark

Amy Geraldine Moore

Marie-Louise Smith

Steven A Smith

Anthony P D W Ford

Nigel P C Walker

Michelle F Browner

Yan Lou

Zhuming Zhang

Rama K Kondru

Nolan James Dewdney

Yingjie Lai

Fancisco X Talamas

Linchin Feng

Clara Jeou Lin

Anthony PDW Ford

Raymond A Hui

Erasmus J Huber

Allan Dorn

Disclosed herein are substituted pyrazole-pyrimidine compounds of Formula I and variants thereof for the treatment, for example, of diseases associated with P2X purinergic receptors: In one embodiment, the P2X3 and/or P2X2/3 antagonists disclosed herein are potentially useful, for example, for the treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.

Substituted pyrazole-pyrimidines, variants thereof, and uses therefore

Provided are novel salts and polymorphs of 5-(2,4-diamino-pyrimidin-5-yloxy)-4-isopropyl-2-methoxy-benzenesulfonamide, which are potentially useful for modulating a condition mediated by a P2X3 or P2X2/3 receptor. Also provided are pharmaceutical formulations and methods of administration and dosing of these salts and polymorphs to subjects in need thereof.

Crystalline salts and polymorphs of a P2X3 antagonist

The present disclosure provides pyrimidine compounds of Formula 1 and uses thereof, for example, for the potential treatment of diseases associated with P2X purinergic receptors: In certain aspects, the present disclosure provides P2X3 and/or P2X2/3 antagonists which are useful, for example, for the potential treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.

Pyrimidines and variants thereof, and uses therefor

Disclosed herein are substituted pyrazole-pyrimidine compounds of Formula (I) and variants thereof for the treatment, for example, of diseases associated with P2X purinergic receptors. In one embodiment, the P2X3 and/or P2X2/3 antagonists disclosed herein are potentially useful, for example, for the treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders. 

The present disclosure provides pyrimidine compounds and uses thereof, for example, for the treatment of diseases associated with P2X purinergic receptors. In certain aspects, the present disclosure provides P2X3 and/or P2X2/3 antagonists which are useful, for example, for the treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.

The present disclosure provides pyrimidine compounds of Formula 1 and uses thereof for example, for the potential treatment of diseases associated with P2X purinergic receptors. In certain aspects, the present disclosure provides P2X3 and/or P2X2/3 antagonists which are useful, for example, for the potential treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders. 

A method of antagonizing P2Xand/or P2Xreceptors or treating a disease misregulation of P2Xand/or P2Xreceptors treating a patient with a compound of formula I wherein R, R, R, R, Rand Rare as defined herein, or a pharmaceutically acceptable salt thereof. wherein, Ris optionally substituted tetrazolyl, Ris optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and R, R, Rand Rare as defined herein. Also provided are methods of using the compounds for treating diseases associated with the P2Xand/or a P2Xreceptor antagonist and methods of making the compounds.

[object Object]

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, Ris optionally substituted pyrazolyl, and R, R, R, R, R, Rand Rare as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2Xand/or a P2Xreceptor antagonists and methods of making the compounds.

A method for treating diseases mediated by a P2Xand/or a P2Xreceptor with compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, Ris an optionally substituted thiazole, oxazole, isothiazole or isoxazole and X, R, R, R, R, R, Rand Rare as defined herein.

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, Ris a group of formula A or formula B, and X, R, R, R, R, R, Rand Rare as defined herein. Also provided are methods of using the compounds for treating diseases mediated by a P2Xand/or a P2Xreceptor antagonist and methods of making the subject compounds.

Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists

Compounds of the formula V: or a pharmaceutically acceptable salt thereof, wherein, Ris optionally substituted phenyl, optionally substituted pyridin-2-yl or optionally substituted thienyl, and R, R, R, Rand Rare as defined herein. Also provided are methods of using the compounds for treating diseases associated with the P2Xand/or a P2Xreceptor antagonist and methods of making the compounds.

Compounds and methods for treating diseases mediated by a P2Xand/or a P2Xreceptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof,wherein D, X, Y, R, R, R, R, R, R, Rand Rare as defined herein.

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, Ris optionally substituted tetrazolyl, Ris optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and R, R, R, RRand Rare as defined herein. Also provided are methods of using the compounds for treating diseases associated with the P2Xand/or a P2Xreceptor antagonist and methods of making the compounds.

The present invention relates to a compound having the general formula (V), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameliorating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

Substituted 1,5-naphthyridines as endonuclease inhibitors

Growing community of inventors

Mountain View, CA, United States of America

Ronald Charles Hawley